Related references
Note: Only part of the references are listed.Dynamic Contrast-Enhanced Computed Tomography to Assess Antitumor Treatment Effects Comparison of Two Contrast Agents With Different Pharmacokinetics
Gregor Jost et al.
INVESTIGATIVE RADIOLOGY (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Personalized oncology: Recent advances and future challenges
Madhu Kalia
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Perfusion MRI for Monitoring the Effect of Sorafenib on Experimental Prostate Carcinoma: A Validation Study
Clemens C. Cyran et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2012)
Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography
K. A. Miles et al.
EUROPEAN RADIOLOGY (2012)
mTOR inhibitors in breast cancer: A systematic review
Flora Zagouri et al.
GYNECOLOGIC ONCOLOGY (2012)
Dynamic Contrast-Enhanced Computed Tomography Imaging Biomarkers Correlated With Immunohistochemistry for Monitoring the Effects of Sorafenib on Experimental Prostate Carcinomas
Clemens C. Cyran et al.
INVESTIGATIVE RADIOLOGY (2012)
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin
Yeun-Chung Chang et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2012)
Novel Agents and Approaches for Advanced Renal Cell Carcinoma
Robert Figlin et al.
JOURNAL OF UROLOGY (2012)
Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability
S. P. Sourbron et al.
PHYSICS IN MEDICINE AND BIOLOGY (2012)
Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer
M. W. Huellner et al.
CANCER IMAGING (2012)
Imaging beyond RECIST: CT and MRI in molecular therapies
Stefan Diederich
CANCER IMAGING (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies
Roy van der Meel et al.
DRUG DISCOVERY TODAY (2010)
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Joline S. W. Lind et al.
EUROPEAN RADIOLOGY (2010)
Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
Laure S. Fournier et al.
RADIOLOGY (2010)
Assessment of Acute Antivascular Effects of Vandetanib with High- Resolution Dynamic Contrast-Enhanced Computed Tomographic Imaging in a Human Colon Tumor Xenograft Model in the Nude Rat
Joo Ho Tai et al.
NEOPLASIA (2010)
In Vivo Monitoring of Angiogenesis Inhibitory Treatment Effects by Dynamic Contrast-Enhanced Computed Tomography in a Xenograft Tumor Model
Hans-Juergen Raatschen et al.
INVESTIGATIVE RADIOLOGY (2009)
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma
Silvana C. Faria et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2007)
Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging
Michael I. Koukourakis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer
ML George et al.
BRITISH JOURNAL OF SURGERY (2001)
Share Paper
